Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02572765
Recruitment Status : Recruiting
First Posted : October 9, 2015
Last Update Posted : June 17, 2019
Sponsor:
Information provided by (Responsible Party):
Giuseppe Lembo, Neuromed IRCCS

Brief Summary:
The purpose of this study is to evaluate the splenic activation in hypertensive patients, as compared to normotensives, using FDG-PET/CT imaging. Moreover, the investigators will investigate whether the splenic metabolic activity relates to the expression of circulating inflammatory proteins (high-sensitivity C-reactive protein [hsCRP]), interleukin-1b (IL-1b), tumor necrosis factor-a (TNF-a) or to immune profiles of activated T cells.

Condition or disease Intervention/treatment
Hypertension Other: PET/CT scan

Layout table for study information
Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension
Actual Study Start Date : January 2, 2018
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2021

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Normotensive
Normotensive subjects
Other: PET/CT scan
PET/CT scan

Hypertensive
Hypertensive subjects
Other: PET/CT scan
PET/CT scan




Primary Outcome Measures :
  1. Splenic metabolic activity [ Time Frame: At enrollment ]
    18FDG uptake in splenic tissue


Secondary Outcome Measures :
  1. Circulating pro-inflammatory markers [ Time Frame: At enrollment ]
    Serum levels of pro-inflammatory cytokines


Biospecimen Retention:   Samples Without DNA
Total blood and serum


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Subjects will be selected from patients who will undergo FDG-PET/CT imaging of chest and abdomen in the Department of Nuclear Medicine of IRCCS Neuromed, accordingly to the following inclusion/exclusion criteria. All the enrolled patients must have an indication for FDG-PET/CT. Approximately 120 hypertensive and normotensive subjects of both genders (at least 45 per group, in order to have the appropriate statistical power) will be included in the study.
Criteria

Inclusion Criteria:

  • absence of prior cancer diagnosis or remission from cancer at the time of FDG-PET/CT imaging (from at least 6 months)
  • age ≥ 30 and ≤ 85 years
  • absence of acute cardio/cerebrovascular disease (myocardial infarction, stroke, transient ischemic attack, revascularization)
  • absence of acute or chronic inflammatory or autoimmune disease
  • diagnosis of presence/absence of hypertension, on the basis of documented medical history

Exclusion Criteria:

  • diabetes
  • atrial fibrillation
  • use of anti-inflammatory drugs in the week preceding the FDG-PET/CT imaging
  • chronic use of anti-inflammatory drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02572765


Contacts
Layout table for location contacts
Contact: Giuseppe Lembo, MD in Cardiology +39 0865.915225 lembo@neuromed.it

Locations
Layout table for location information
Italy
IRCCS Neuromed Recruiting
Pozzilli, (is), Italy, 86077
Principal Investigator: Giuseppe Lembo, prof., MD, PhD         
Sub-Investigator: Daniela Carnevale, PhD         
Sponsors and Collaborators
Neuromed IRCCS
Layout table for additonal information
Responsible Party: Giuseppe Lembo, prof. Giuseppe Lembo, Neuromed IRCCS
ClinicalTrials.gov Identifier: NCT02572765    
Other Study ID Numbers: LMB05
First Posted: October 9, 2015    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: June 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases